TropIKA.net coverage
|
Session reportsMonday 2 Nov 2009 Plenary session 1Symposium 2: RITAMTraditional medicines for malariaSymposium 3: US CDC-USAIDEntomological monitoring of vector control activities under the US president’s malaria initiativeScientific Session 1Treatment and ControlScientific Session 4Drugs and resistance: clinical trialsScientific Session 6Socio-Economic AspectsSymposium 4 - MALARIAGENToward genomic epidemiology of malaria: progress challenges and potentialSymposium 5 - PMIThe President’s Malaria initiative: A collaborative approach to scaling up malaria control interventionsSymposium 8 - PATH-MVI, MMVTen Years of Malaria PDPs: Achievements, Lessions Learned, and Challenges for the FutureSymposium 44 - MMV, Pfizer, sigma-tauAdvancing and Optimizing Malaria Therapy with the Promise of Multiple First Line OptionsScientific Session 9Health Systems ResearchControversies IPresumptive treatment for malaria: time for a changeTuesday 3 Nov 2009 Plenary session 2Symposium 13: ANTIMALEarly Stage Drug DiscoverySymposium 14: GMZ2GMZ2 Symposium on Malaria VaccinesSymposium 15: NovartisCoartem®: Malaria diagnosis, treatment and patient benefit from community deploymentSymposium 18: MMV-PSI, WHOImproving access to ACTs II: Malaria case management in a changing epidemiologySymposium 19: WARNWorldWide Antimalarial Resistance Network, WWARN: First Steps toward realizationSymposium 20: IVCCMonitoring and Evaluation of Vector controlSymposium 21: Wellcome TrustPoor antimalarial drug quality – Malaria’s Deadly Fifth ColumnSymposium 23: Wellcome TrustMalaria in Pregnancy ConsortiumScientific Session 12Immunology: Pregnancy Associated MalariaScientific Session 13Epidemiology: Assessment of Malaria BurdenScientific Session 14Health Systems ResearchScientific Session 16Treatment and ControlScientific Session 17Late BreakersScientific Session 18Research Capacity StrengtheningScientific Session 19Health Research EthicsControversy IIAttenuated parasite vaccine: When and How?Wednesday 4 Nov 2009 Plenary session 3Symposium 25: MEPHAClinical experience with a new, fixed-dose ACT for the treatment of malaria in small childrenSymposium 26: malERAThe Malaria Eradication Research Agenda (malERA)Symposium 27: PATH-MVIMalaria vaccine introduction: informing country level decision makingSymposium 28: AMFmThe Affordable Medicines Facility – malaria – (AMFm)Symposium 29: International Research Institute for Climate and Society (IRI)Building Capacity to Use Climate and Environmental Information for Improving Health OutcomesScientific Session 20Drug discovery and other moleculesScientific Session 22Vector Control and ResistanceScientific Session 23Vector GeneticsControversies IIIMalaria Eradication / EliminationThursday 5 Nov 2009 Plenary session 4Symposium 32: PATH-MVI, MMVPartnering to Strengthen Endemic Country Capacity through Clinical TrialsSymposium 33: AMANETHealth Research EthicsSymposium 34: ACT ConsortiumAnswering key questions on ACT drug delivery in Africa: an introduction to the work of the ACT consortiumScientific Session 24Parasite Biology: Parasite GeneticsScientific Session 25Vector EcologyScientific Session 26Drugs and ResistanceScientific Session 28Epidemiology and TransmissionSymposium 35: STIModelling malaria dynamics: The untapped potential for malaria control programmesSymposium 36: USAID-RTIIntegrated Vector Management (IVM)Symposium 37: CCM Operations Research GroupIntegrated community case management of malaria. Pneumonia and diarrhea: A review of recent evidenceSymposium 38: ANTIMALSession Two: Anti-Malarial Drug DevelopmentSymposium 39: Oxford-USMilitaryVectored Vaccines for MalariaScientific Session 33VectorsFriday 6 Nov 2009 Plenary session 5Symposium 41: EU-TDR-ANDIImproved tools for the elimination of Malaria in Africa: Research for New drugs and Innovative DiagnosticsSymposium 42: GSK-PATHThe RTS, S/AS Malaria Vaccine Candidate at the Pivotal Phase III Evaluation StageScientific Session 36Socio-Economic Aspects IIScientific Session 38Parasite-Vector Interaction and SystematicsScientific Session 39Drugs and Resistance: ACTsScientific Session 40Clinical EpidemiologyScientific Session 41Immunology: AntibodiesScientific Session 42TDR Presentations |
Meeting blog20 Nov 2009
Podcasts from Nairobi
|